|
Squamous cell carcinoma of skin
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
This model provides a mechanistic framework for understanding how Cbp/p300 loss of function mutations impact on skin tumorigenesis and suggests potential therapeutic options in CBP/p300 mutated human cSCC.
|
31397888 |
2020 |
|
Multiple Myeloma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
This strategy also appeared to be more broadly applicable as SGC-CBP30 could re-sensitize two resistant HMCLs with low but detectable CRBN expression to lenalidomide, suggesting that targeting CBP/E300 is a promising approach to restore IMiD sensitivity in MM with detectable CRBN expression.
|
30741931 |
2019 |
|
Osteosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Ras-ERK1/2 Signaling Promotes The Development Of Osteosarcoma By Regulating H2BK12ac Through CBP.
|
31695502 |
2019 |
|
Pulmonary Fibrosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
The purpose of this study is to explore the target cells of Wnt/β-catenin inhibition in pulmonary fibrosis and to examine the antifibrotic effect of the novel inhibitor PRI-724 specifically disrupting the interaction of β-catenin and CBP.
|
31298961 |
2019 |
|
Sarcoma 180
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The copper complex CBP-01 showed in vitro antitumor activity with IC<sub>50</sub>s values of 7.4 μM against Sarcoma 180 and 26.4 against murine myoblast cells, displaying selectivity toward the tumor cell tested in vitro (SI > 3).
|
30784909 |
2019 |
|
Secondary malignant neoplasm of bone
|
0.010 |
Biomarker
|
disease |
BEFREE |
These results suggest that small molecules targeting CREB-CBP interaction to inhibit CREB-mediated gene transcription might be a potential approach for the treatment of breast cancer bone metastasis.
|
30461194 |
2019 |
|
Muscular Dystrophy, Facioscapulohumeral
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Facioscapulohumeral muscular dystrophy (FSHD) results from mutations causing overexpression of the transcription factor, DUX4, which interacts with the histone acetyltransferases, EP300 and CBP.
|
31535023 |
2019 |
|
Non-alcoholic Fatty Liver Disease
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Abbreviations: WAT: white adipose tissue; PPAR: Peroxisome proliferators-activated receptor; RXR: retinoid X receptors; mTORC1: mechanistic target of rapamycin complex 1; PPRE: PPAR-responsive regulatory elements; NAFLD: nonalcoholic fatty liver disease; LPL: lipoprotein lipase; FGF21: fibroblast growth factor 21; BAT: brown adipose tissue; UCP1: uncoupling protein 1; LPC(16:0): 1-palmitoyl lysophosphatidylcholine; C/EBP: CCAAT-enhancer binding proteins; STAT5A: signal transduction and activator of transcription 5A; APO apolipoptotein; CBP: cAMP response element-binding protein-binding protein; PGC1A: PPARγ coactivator protein 1a; HFD: high-fat diet; TG: triglyceride; VLDL: very low density lipoprotein; HDL: high density lipoprotein.
|
30572788 |
2019 |
|
Osteosarcoma of bone
|
0.010 |
Biomarker
|
disease |
BEFREE |
Ras-ERK1/2 Signaling Promotes The Development Of Osteosarcoma By Regulating H2BK12ac Through CBP.
|
31695502 |
2019 |
|
Childhood Osteosarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Ras-ERK1/2 Signaling Promotes The Development Of Osteosarcoma By Regulating H2BK12ac Through CBP.
|
31695502 |
2019 |
|
Tumor Immunity
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
Our findings uncover a role of CBP/EP300-BRD in intratumoral MDSCs that may be targeted therapeutically to boost anti-tumor immunity.
|
30943407 |
2019 |
|
Triple-Negative Breast Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
In addition, these copper complexes decrease the stemness of triple-negative breast cancer cells and have synergistic effects with CBP on TNBC cells, indicating their great potential as a novel therapy for triple-negative breast cancer.
|
31531205 |
2019 |
|
Rheumatoid Arthritis
|
0.010 |
Biomarker
|
disease |
BEFREE |
Results proposed that inhibition of p300/CBP could be new therapeutic targets for RA.
|
29217191 |
2018 |
|
Hepatitis B
|
0.010 |
Biomarker
|
disease |
BEFREE |
The hepatitis B virus (HBV) HBx and the human T cell lymphotropic virus-1 (HTLV-1) Tax proteins inhibit p53 activity through the modulation of p300/CBP nuclear factors, while the Kaposi's sarcoma herpesvirus (HHV8) LANA, vIRF-1 and vIRF-3 proteins have been shown to destabilize the oncosuppressor, causing a decrease in its levels in the infected cells.
|
29932446 |
2018 |
|
Hypertensive disease
|
0.010 |
Biomarker
|
group |
BEFREE |
Longer CBP time, aortic cross clamp time and presence of pulmonary hypertension are risk factors for higher morbidity in this group.
|
28709919 |
2018 |
|
Malignant neoplasm of stomach
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The loss of p300/CBP-associated protein (PCAF) expression is associated with poor clinical outcome in gastric cancer, and a potential bio-marker for invasive and aggressive tumors.
|
29670108 |
2018 |
|
Kaposi Sarcoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The hepatitis B virus (HBV) HBx and the human T cell lymphotropic virus-1 (HTLV-1) Tax proteins inhibit p53 activity through the modulation of p300/CBP nuclear factors, while the Kaposi's sarcoma herpesvirus (HHV8) LANA, vIRF-1 and vIRF-3 proteins have been shown to destabilize the oncosuppressor, causing a decrease in its levels in the infected cells.
|
29932446 |
2018 |
|
Fibrosis, Liver
|
0.010 |
Biomarker
|
disease |
BEFREE |
p300/CBP as a Key Nutritional Sensor for Hepatic Energy Homeostasis and Liver Fibrosis.
|
29862292 |
2018 |
|
Malignant Head and Neck Neoplasm
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Functional and genomic analyses reveal therapeutic potential of targeting β-catenin/CBP activity in head and neck cancer.
|
30029671 |
2018 |
|
Tumor Initiation
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
CSCs are thought to be responsible for tumor initiation and drug resistance. cAMP-response element-binding (CREB) binding protein (CREBBP or CBP) has been implicated in CSC biology and may provide a novel therapeutic target in TNBC.
|
30572639 |
2018 |
|
Stomach Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The loss of p300/CBP-associated protein (PCAF) expression is associated with poor clinical outcome in gastric cancer, and a potential bio-marker for invasive and aggressive tumors.
|
29670108 |
2018 |
|
Central Serous Chorioretinopathy
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
<i>Conclusion:</i> CBP/β-catenin/FOXM1 transcriptional activity plays an important role in TNBC drug resistance and CSC phenotype.
|
30572639 |
2018 |
|
Head and Neck Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Functional and genomic analyses reveal therapeutic potential of targeting β-catenin/CBP activity in head and neck cancer.
|
30029671 |
2018 |
|
Carcinoma, Transitional Cell
|
0.010 |
Biomarker
|
disease |
BEFREE |
In urothelial carcinoma (UC), p300 and CBP are often mutated, whereas the GNAT family HATs GCN5 and PCAF (General Control Nonderepressible 5, p300/CBP-Associated Factor) are often upregulated.
|
28678170 |
2017 |
|
Adenocarcinoma Of Esophagus
|
0.010 |
Biomarker
|
disease |
BEFREE |
Simultaneous inhibition of p300/CBP and Notch has a synergistic effect in esophageal adenocarcinoma.
|
28625977 |
2017 |